By Dr Derek Jellinek
07 August 2023, 8:00 AM
ResMed Inc's (ASX:RMD) 4Q was mixed, as strong sales across all product lines failed to translate into operating leverage.
Read more...
By Dr Derek Jellinek
28 June 2023, 8:00 AM
Sonic Healthcare (ASX:SHL) is acquiring Switzerland-based Synlab Suisse for CHF150m (cA$250m) funded via existing CHF cash and debt.
Read more...
By Iain Wilkie
22 June 2023, 8:00 AM
Pro Medicus’ (ASX:PME) share price has rallied over the last few weeks beyond the bounds of our Hold recommendation structure.
Read more...
By Scott Power
08 June 2023, 8:00 AM
Ebos Group (ASX:EBO) has announced it has lost the contract to supply wholesale PBS medicines to Chemist Warehouse (CW) from July 2024.
Read more...
By Scott Power
01 June 2023, 8:00 AM
We have been looking for an opportunity to upgrade Nanosonics (ASX:NAN) back to Add (from Hold) and given the recent share price weakness, we now have ~10% upside to our increased target price.
Read more...
By Scott Power
05 May 2023, 8:00 AM
Nanosonics' (ASX:NAN) share price has gone through our target price and as a result we have moved our recommendation back to Hold (from Add).
Read more...
By Dr Derek Jellinek
04 May 2023, 8:00 AM
A nine-month FY23 trading update from Ramsay Health Care (ASX:RHC) highlighted improving volumes across all regions on increased surgical activity, although margins and profit lagged.
Read more...
By Dr Derek Jellinek
01 May 2023, 8:00 AM
ResMed (ASX:RMD) 3Q was ahead of expectations on strong sales across all product lines, but with GM headwinds and higher opex limiting robust operating leverage.
Read more...
By Dr Derek Jellinek
24 February 2023, 8:00 AM
Ramsay Health Care's (ASX:RHC) 1H23 results beat, with revenue gains across all regions on increased surgical activity, although profit was aided by NRIs, acquisitions and government payments.
Read more...
By Scott Power
24 February 2023, 8:00 AM
Nanosonics (ASX:NAN) posted a solid 1H23 result which was in line with forecasts and FY23 guidance was reconfirmed.
Read more...